Host Fred Goldstein invites Jennifer Mathieu, Senior Vice President, Professional & Government Affairs to discuss the Prescription Digital Therapeutics Act, the Medicaid MVPs for Patient Act and other AMCP legislative priorities.
On January 31, 2019, HHS proposed sweeping changes to the current system for medication pricing and contracting by PBM companies in federal programs. This summary reviews OIG's proposal to eliminate the safe harbor protections for rebates that exist in the federal Anti-Kickback Statute (AKS) and replace these protections with proposed new safe harbors allowing for point-of-sale discounts to beneficiaries and for manufacturer-paid service fees to PBMs.
AMCP CEO Blog: The FDA approved 46 novel drugs in 2017, a 21-year high. However, it could take as long as six months for some of these groundbreaking medicines to reach patients.
